ABI-007 In Combination With Bevacizumab in Women With Metastatic Breast Cancer
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of weekly ABI-007 in
combination with bevacizumab.
The evaluation of progression-free survival of weekly ABI-007 in combination with bevacizumab
for patients with previously untreated advanced/metastatic breast cancer.